Skip to main content

Table 2 Patient Characteristics, Response and Steroid Dose

From: Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Pt # Grade OR KPS # of cycles of pembro MGMT Status IDH Status 1p/19q ML Steroids at initiation Steroid dose at initiation (in prednisone equivalence) # of cycles with steroids Con
Bev
Prev Bev
0 <20 ≥20
1 III PR 90 4 unmethylated WT N/A 6 N X    2 Y Y
2 IV PR 80 4 unmethylated N/A N/A 6 Y    X 1 Y N
3 III SD 90 14 methylated WT intact 6 N X    0 N N
4 III SD 70 10 unmethylated MUT N/A 3 Y    X 1 Y Y
5 IV SD 90 14 unmethylated WT N/A 12 N X    5 Y Y
6 IV SD 100 4 methylated N/A N/A 13 N X    0 N Y
7 IV SD 100 1 N/A WT N/A N/A Y    X 1 Y Y
8 III PD 90 6 N/A MUT co-del 5 Y   X   1 N N
9 III PD 60 5 N/A MUT co-del 58 Y   X   0 Y Y
10 III PD 60 3 unmethylated MUT N/A 7 N X    2 N N
11 III PD 70 3 unmethylated WT N/A 5 Y   X   3 Y Y
12 III PD 90 2 unmethylated WT intact 15 Y   X   2 Y N
13 III PD 90 2 unmethylated MUT N/A 7 Y    X 2 Y Y
14 III PD N/A 1 methylated MUT N/A 5 N X    0 N Y
15 IV PD 90 5 methylated MUT N/A 11 Y    X 2 N N
16 IV PD 60 5 unmethylated WT intact 10 Y    X 2 Y Y
17 IV PD 50 4 N/A N/A N/A N/A N X    0 Y Y
18 IV PD 90 3 N/A MUT N/A 9 Y    X 3 Y Y
19 IV PD 90 3 unmethylated N/A N/A 4 Y    X 1 Y Y
20 IV PD 90 3 N/A N/A N/A N/A N X    1 Y Y
21 IV PD 70 2 unmethylated WT N/A 13 Y   X   2 Y Y
22 IV PD 80 2 unmethylated MUT N/A 5 N X    0 Y Y
23 IV PD 80 2 N/A WT N/A N/A N X    1 Y Y
24 N/A PD 70 2 N/A N/A N/A N/A N X    1 Y Y
25 IV N/A 60 1 N/A MUT intact 19 Y    X 1 Y Y
  1. Abbreviations: Pt: Patient; OR: Objective response; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; KPS: Karnofsky performance score; Pembro: pembrolizumab; N/A: not applicable or unknown; MGMT methylated: methylated; MGMT unmethylated: unmethylated; IDH mutant: MUT; IDH wild type: WT; 1p19q intact: intact; 1p19q codeleted: Co-del; ML: mutational load by MSK impact; Y: yes; N: no; X: indicates steroid dose at initiation; Con Bev: Concomitant bevacizumab; Prev Bev: previously progressed on bevacizumab treatment